Mechanism of Action
Inhibits lipogenesis without affecting IGF-1 levels, glucose homeostasis, or inducing insulin resistance. Acts via beta-3 adrenergic receptor pathway in adipose tissue.
Clinical Use
Body composition, fat loss (compounding, off-label). FDA GRAS status supports favorable safety profile.
Contraindications
Pregnancy. Active malignancy. Known hypersensitivity.
Evidence Summary
Phase II showed 2.8kg vs 0.8kg placebo weight loss. Phase IIb (n=536) failed primary endpoint. US FDA GRAS designation. Australian TGA novel food status.
Key Studies
- 1.Wittert GA et al., 2004 (Phase II) — 1mg/d group: 2.8kg vs 0.8kg placebo. Superior side effect profile. n=300, Phase II RCT
- 2.OPTIONS Study, 2007 (Phase IIb) — FAILED to demonstrate statistically significant weight loss at 24 weeks. Development terminated. n=536, Phase IIb RCT
Evidence Gaps
Failed pivotal Phase IIb trial ended clinical development in 2007. No ongoing pharmaceutical development.
Emerging Research
Cartilage repair and osteoarthritis applications emerging. Australian TGA novel food status enables certain uses.